Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. (EVMN) reported insider ownership changes tied to its initial public offering. RA Capital–affiliated entities converted Series C Preferred Stock into Common Stock immediately prior to the IPO and also bought additional shares in the offering.
The Fund and RA Capital Nexus Fund III converted preferred stock into 1,517,329 and 691,441 shares of Common Stock, respectively, and then purchased 1,157,096 and 92,904 additional Common shares at $16 per share. These holdings are reported as indirectly owned, with RA Capital Management, L.P., its general partner, and related individuals disclaiming beneficial ownership beyond their pecuniary interests. The reporting persons are identified as both a director affiliate and 10% owner of Evommune.
Evommune, Inc. insider LSP 7 Management B.V., as director of LSP 7 Cooperatief U.A., reported multiple equity transactions dated 11/07/2025. All outstanding shares of Series A, Series B, and Series C preferred stock automatically converted into common stock immediately before Evommune’s initial public offering, for no additional consideration, at fixed ratios for each series. Following these conversions, the reporting person bought an additional 1,562,500 shares of common stock at $16 per share. After the reported transactions, LSP 7 Cooperatief U.A. directly held 4,929,633 shares of Evommune common stock.